Skip to main content
SpringerLink
Log in

Anticoagulation Therapy in ICU Patients

  • Chapter
  • First Online:
Hemocoagulative Problems in the Critically Ill Patient

Abstract

Most patients admitted to an ICU have multiple risk factors for thromboembolic complications, which are very often present in the guise of deep venous thrombosis (DVT) and/or pulmonary thromboembolism (PTE). Risks factors may be present before the ICU admission (advanced age, malignancy, major surgery, major trauma), or may be related to the ICU stay (such as mechanical ventilation and central venous catheters). In such settings, there are strong indications for prolonged thromboprophylaxis and/or treatment of thrombotic complications. This is achieved by a number of pharmacological and nonpharmacological provisions, each having specific advantages and shortcomings. To date, heparin and vitamin K antagonists are the two most widely used measures for both prevention and treatment of DVT and PTE. Critically ill patients are peculiar in having altered pharmacokinetic and pharmacodynamic variability. This variability can lead to unpredictable drug effects, greater toxicity, and increased potential for adverse drug effects associated with disorders of coagulation. ICU patients can receive simultaneously several different medications throughout their stay, increasing the potential for drug interactions or a synergistic/enhanced response.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Illingworth C, Timmons S (2007) An audit of intermittent pneumatic compression (IPC) in the prophylaxis of asymptomatic deep vein thrombosis (DVT). J Perioper Pract 17(11):522–524, 526–528

    Google Scholar 

  2. Harris LM, Curl GR, Booth FV, Hassett JM Jr, Leney G, Ricotta JJ (1997) Screening for asymptomatic deep vein thrombosis in surgical intensive care patients. J Vasc Surg 26(5):764–769

    Article  PubMed  CAS  Google Scholar 

  3. Ibrahim EH, Iregui M, Prentice D, Sherman G, Kollef MH, Shannon W (2002) Deep vein thrombosis during prolonged mechanical ventilation despite prophylaxis. Crit Care Med 30(4):771–774

    Article  PubMed  Google Scholar 

  4. Geerts WH, Code KI, Jay RM, Chen E, Szalai JP (1994) A prospective study of venous thromboembolism after major trauma. N Engl J Med 331(24):1601–1606

    Article  PubMed  CAS  Google Scholar 

  5. Joynt GM, Kew J, Gomersall CD, Leung VY, Liu EK (2000) Deep venous thrombosis caused by femoral venous catheters in critically ill adult patients. Chest 117(1):178–183

    Article  PubMed  CAS  Google Scholar 

  6. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG (2004) Prevention of venous thromboembolism: the Seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126(Suppl 3):338S–400S

    Article  PubMed  CAS  Google Scholar 

  7. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW, American college of Chest Physicians (2008) Prevention of venous thromboembolism: American College of chest physicians evidence-based clinical practice guidelines, 8th edn. Chest 133(Suppl 6):381S-453S

    Google Scholar 

  8. Vardi M, Zittan E, Bitterman H (2009) Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism. Cochrane Database Syst Rev 7(4):CD006771

    Google Scholar 

  9. McGarry LJ, Stokes ME, Thompson D (2006) Outcomes of thromboprophylaxis with enoxaparin versus unfractionated heparin in medical inpatients. Thromb J 27(4):17

    Article  Google Scholar 

  10. Bauersachs R, Schellong SM, Haas S, Tebbe U, Gerlach HE, Abletshauser C, Sieder C, Melzer N, Bramlage P, Riess H (2011) Prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Thromb Haemost 105(6):981–988 [Epub 2011 Apr 20]

    Article  PubMed  CAS  Google Scholar 

  11. Antithrombotic therapy for venous thromboembolic disease: American college of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edn.)

    Google Scholar 

  12. Hirsch DR, Ingenito EP, Goldhaber SZ (1995) Prevalence of deep venous thrombosis among patients in medical intensive care. JAMA 274(4):335–337

    Article  PubMed  CAS  Google Scholar 

  13. Cook D, Meade M, Guyatt G, Walter SD, Heels-Ansdell D, Geerts W, Warkentin TE, Cooper DJ, Zytaruk N, Vallance S, Berwanger O, Rocha M, Qushmaq I, Crowther M (2011) Prophylaxis for thromboembolism in critical care trial protocol and analysis plan. J Crit Care 26(2):223.e1–9

    Google Scholar 

  14. Hirsh J, Gordon G, Gregory WA, Robert H, Holger JS (2008) American college of chest physicians evidence-based clinical practice guidelines (8th edn.) Chest 134(4):892

    Google Scholar 

  15. Hirsh J, Guyatt G, Gregory WA, Robert H, Holger JS (2008) Antithrombotic and thrombolytic therapy: American college of chest physicians evidence-based clinical practice guidelines (8th edn.) Chest 133:110S–112S. doi:10.1378/chest.08-0652

  16. Hillis C, Warkentin TE, Taha K, Eikelboom JW (2011) Chills and limb pain following administration of low-molecular-weight heparin for treatment of acute venous thromboembolism. Am J Hematol 86(7):603–606. doi:10.1002/ajh.22043

    Article  PubMed  Google Scholar 

  17. Phung OJ, Kahn SR, Cook DJ, Murad MH (2011) Dosing frequency of unfractionated heparin thromboprophylaxis: a meta-analysis. Chest [Epub ahead of print]

    Google Scholar 

  18. Quinlan DJ, McQuillan A, Eikelboom JW (2004) Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials. Ann Intern Med 140(3):175–183

    PubMed  CAS  Google Scholar 

  19. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G, American College of Chest Physicians (2008) Pharmacology and management of the vitamin K antagonists: American college of chest physicians evidence-based clinical practice guidelines (8th edn.). Chest 133(Suppl 6):160S–198S

    Google Scholar 

  20. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G (2008) Pharmacology and management of the vitamin K antagonists: American college of chest physicians evidence-based clinical practice guidelines (8th edn.) Chest 133:160S–198S. doi:10.1378/chest.08-0670

  21. Tafur AJ, McBane R, Wysokinski WE, Litin S, Daniels P, Slusser J, Hodge D, Beckman MG, Heit JA (2012) Predictors of major bleeding in peri-procedural anticoagulation management. J Thromb Haemost 10(2):261–267. doi:10.1111/j.1538-7836.2011.04572.x

    Article  PubMed  CAS  Google Scholar 

  22. Falvo N, Bonithon-Kopp C, Rivron Guillot K, Todolí JA, Jiménez-Gil M, Di Micco P, Monreal M, The RIETE investigators (2011) Heparin-associated thrombocytopenia in 24,401 patients with venous thromboembolism. Findings from the RIETE registry. J Thromb Haemost doi:10.1111/j.1538-7836.2011.04402.x

  23. Cuker AJ (2011) Heparin-induced thrombocytopenia: present and future. Emerg Trauma Shock 4(1):97–102

    Article  Google Scholar 

  24. Kato S, Takahashi K, Ayabe K, Samad R, Fukaya E, Friedmann P, Varma M, Bergmann SR (2011) Heparin-induced thrombocytopenia: analysis of risk factors in medical inpatients. J Thromb Thrombolysis 31(3):353-66. doi:10.1111/j.1365-2141.2011.08746.x

    Google Scholar 

  25. Greinacher A, Juhl D, Strobel U, Wessel A, Lubenow N, Selleng K, Eichler P, Warkentin TE (2007) Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemost 5(8):1666–1673 [Epub 2007 May 7]

    Google Scholar 

  26. Kappers-Klunne MC, Boon DM, Hop WC, Michiels JJ, Stibbe J, van der Zwaan C, Koudstaal PJ, van Vliet HH (1997) Heparin-induced thrombocytopenia and thrombosis: a prospective analysis of the incidence in patients with heart and cerebrovascular diseases. Br J Haematol. 96(3):442–446

    Article  PubMed  CAS  Google Scholar 

  27. Kahl K, Heidrich H (1998) The incidence of heparin-induced thrombocytopenias. Int J Angiol 7(3):255–257

    Article  PubMed  Google Scholar 

  28. Hirsh J, Warkentin TE, Raschke R, Granger C, Ohman EM, Dalen JE (1998) Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest. 114(Suppl 5):489S–510S

    Article  PubMed  CAS  Google Scholar 

  29. Kurtz LE, Yang S (2007) Bilateral adrenal hemorrhage associated with heparin induced thrombocytopenia. Am J Hematol 82(6):493–494

    Article  PubMed  Google Scholar 

  30. Schmidt OH, Lang W (1997) Heparin-induced thrombocytopenia with thromboembolic arterial occlusion treated with recombinant hirudin. N Engl J Med 337(19):1389

    Article  PubMed  CAS  Google Scholar 

  31. Matsuo T, Koide M, Kario K (1997) Application of argatroban, direct thrombin inhibitor, in heparin-intolerant patients requiring extracorporeal circulation. Artif Organs 21(9):1035–1038

    Article  PubMed  CAS  Google Scholar 

  32. Lewis BE, Rangel Y, Fareed J (1998) The first report of successful carotid stent implant using argatroban anticoagulation in a patient with heparin-induced thrombocytopenia and thrombosis syndrome: a case report. Angiology 49(1):61–67

    Article  PubMed  CAS  Google Scholar 

  33. Amiral J, Lormeau JC, Marfaing-Koka A, Vissac AM, Wolf M, Boyer-Neumann C, Tardy B, Herbert JM, Meyer D (1997) Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis 8(2):114–117

    Article  PubMed  CAS  Google Scholar 

  34. Brown DL et al (2001) Meta-analysis of effectiveness and safety of abciximab versus eptafibatide or tirofiban in percutaneous coronary intervention. Am J Cardiol 87:537–541

    Article  PubMed  CAS  Google Scholar 

  35. Topol EJ et al (2001) Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 344:1888–1894

    Article  PubMed  CAS  Google Scholar 

  36. Coller BS (2001) Anti-GPIIb/IIIa: current strategies and future directions. Thromb Haemost 86:427–443

    PubMed  CAS  Google Scholar 

  37. Bosh X, Marrugat J. Platelet glycoprotein IIb/IIIa blockers for percutaneous coronary revascularization, and unstable angina and non-ST-segment elevation myocardial infarction

    Google Scholar 

  38. Ferro M, Crivello R, Rizzotti M (2000) Comparison of subcutaneous calcium heparin and acetylsalicylic acid in the prevention of ischemic events and death after myocardial infarction: a randomized trial in a consecutive series of 90 patients. Heart Dis 2(4):278–281

    PubMed  CAS  Google Scholar 

  39. Sawaya FJ, Musallam KM, Arnaout S, Rabah A (2011) To RE-LY or not to rely. In: Sawaya J (ed) Int J Cardiol, Switching patients from warfarin to dabigatran therapy

    Google Scholar 

  40. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L (2009) RE-LY steering committee and investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139–1151 [Epub 2009 Aug 30]

    Article  PubMed  CAS  Google Scholar 

  41. Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, Pfeffer M, Hohnloser S, Yusuf S (2006) ACTIVE writing group of the ACTIVE investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE W): a randomised controlled trial. Lancet 367(9526):1903–1912

    Article  PubMed  CAS  Google Scholar 

  42. Lindblad B, Sternby NH, Bergqvist D (1991) Incidence of venous thromboembolism verified by necropsy over 30 years. BMJ 302(6778):709–711

    Article  PubMed  CAS  Google Scholar 

  43. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Forcier A (1992) The prevalence of risk factors for venous thromboembolism among hospital patients. Arch Intern Med 152(8):1660–1664

    Article  PubMed  Google Scholar 

  44. Lindblad B, Bergqvist D, Nordström M, Kjellström T, Björgell O, Nylander G, Sternby NH, Anderson H (1992) A survey in Malmö. The frequency of venous thromboembolism has not changed during the last 30 years. Lakartidningen. 89(37):2941–2942, 2947

    Google Scholar 

  45. Sandler DA, Martin JF (1989) Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis? J R Soc Med 82(4):203–205

    Google Scholar 

  46. The SCATI (Studio sulla Calciparina nell’Angina e nella Trombosi Ventricolare nell’Infarto) Group (1989) Randomised controlled trial of subcutaneous calcium-heparin in acute myocardial infarction. Lancet 2(8656):182–186

    Google Scholar 

  47. Kase CS, Albers GW, Bladin C, Fieschi C, Gabbai AA, O’Riordan W, Pineo GF, PREVAIL Investigators (2009) Neurological outcomes in patients with ischemic stroke receiving enoxaparin or heparin for venous thromboembolism prophylaxis: subanalysis of the prevention of VTE after acute ischemic stroke with LMWH (PREVAIL) study. Stroke 40(11):3532–3540. [Epub 2009 Aug 20]

    Google Scholar 

  48. Sandercock PA, Counsell C, Gubitz GJ, Tseng MC (2008) Antiplatelet therapy for acute ischaemic stroke. Kochrane Database Syst Rev 16;(3):CD000029

    Google Scholar 

  49. Morris RJ, Woodcock JP (2010) Intermittent pneumatic compression or graduated compression stockings for deep vein thrombosis prophylaxis? A systematic review of direct clinical comparisons. Ann Surg 251(3):393–396

    Article  PubMed  Google Scholar 

  50. Cohen A (1997) Interpretation of IST and CAST stroke trials. International stroke trial. Chinese acute stroke trial. Comment on: Lancet. 349(9065):1569–1581, 350(9075):440, author reply 443–444

    Google Scholar 

  51. Low molecular weight heparinoid ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. The Publications Committee for the trial of ORG 10172 in acute stroke treatment (TOAST) Investigators. JAMA. 279(16):1265–1272

    Google Scholar 

  52. Goldstein JN, Gilson AJ (2011) Critical care management of acute intracerebral hemorrhage. Curr Treat Options Neurol 13(2):204–216

    Article  PubMed  Google Scholar 

  53. Paciaroni M, Agnelli G, Venti M, Alberti A, Acciarresi M, Caso V (2011) Efficacy and safety of anticoagulants in the prevention of venous thromboembolism in patients with acute cerebral hemorrhage: a meta-analysis of controlled studies. J Thromb Haemost 9(5):893–898. doi:10.1111/j.1538-7836.2011.04241.x

    Article  PubMed  CAS  Google Scholar 

  54. Fuster V, Rydén LE, Cannom DS, Harry CJ, Anne CB, Kenneth EA, Jonathan HL, Kay NG, Jean-Yves LH, James LE, Olsson BS, Eric PN, Luis JT, Samuel WL, Smith SC, Silvia GP (2011) ACCF/AHA/HRS focused updates incorporated Into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. Circulation 123:e269–e367

    Google Scholar 

  55. Daniel ES, Albers GW, Dalen JE, Fang MC, Alan SG, Jonathan LH, Gregory YHL, Warren JM (2008) Antithrombotic therapy in atrial fibrillation: American college of chest physicians evidence-based clinical practice guidelines (8th edn.). Chest 133;546S-592S. doi:10.1378/chest.08-0678

  56. Antonio R, Marcello D, Alboni P, Bertaglia E, Botto G, Brignole M, Cappato R, Capucci A, Del Greco M, de Ponti R, Di Biase M, Di Pasquale G, Michele G, Lombardi F, Sakis T, Tritto M (2011) AIAC 2010 guidelines for the management and treatment of atrial fibrillation. G Ital Cardiol 12(Suppl 1):7–69

    Google Scholar 

  57. Ezekowitz MD, Connolly S, Parekh A, Reilly PA, Varrone J, Wang S, Oldgren J, Themeles E, Wallentin L, Yusuf S (2009) Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J 157(5):805–810, 810.e1-2

    Google Scholar 

  58. Rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of the ROCKET AF study. Am Heart J 159(3):340–347.e1

    Google Scholar 

  59. Bates DW, Cullen DJ, Laird N et al (1995) Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA 274:29–34

    Article  PubMed  CAS  Google Scholar 

  60. Kopp BJ, Erstad BL, Allen ME et al (2006) Medication errors and adverse drug events in an intensive care unit: direct observation approach for detection. Crit Care Med 34:415–425

    Article  PubMed  Google Scholar 

  61. Leape LL, Brennan TA, Laird N et al (1991) The nature of adverse events in hospitalized patients. Results of the Harvard Medical practice study II. N Engl J Med 324:377–384

    Article  PubMed  CAS  Google Scholar 

  62. Cullen DJ, Sweitzer BJ, Bates DW et al (1997) Preventable adverse drug events in hospitalized patients: a comparative study of intensive care and general care units. Crit Care Med 25:1289–1297

    Article  PubMed  CAS  Google Scholar 

  63. Cohen AT, Alikhan R (2005) Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. Thromb Haemost 94(4):750–759

    PubMed  Google Scholar 

  64. Leizorovicz A, Mismetti P (2004) Preventing venous thromboembolism in medical patients. Circulation 110:IV-13-IV-19

    Google Scholar 

  65. Bechtold H, Janssen D (2004) Anticoagulation with low-molecular-weight heparin in patients with heart diseases. Eur J Med Res 9(4):186–198

    PubMed  CAS  Google Scholar 

  66. Baum GL, Fisher FD (1960) The relationship of fatal pulmonary insufficiency with cor pulmonale, rightsided mural thrombi and pulmonary emboli: a preliminary report. Am J Med Sci 240:609–612

    PubMed  CAS  Google Scholar 

  67. Greene R, Zapol WM, Snider MT, Reid L, Snow R, O’Connell RS, Novelline RA (1981) Early bedside detection of pulmonary vascular occlusion during acute respiratory failure. Am Rev Respir Dis 124(5):593–601

    PubMed  CAS  Google Scholar 

  68. Lip GY, Lane DA (2010) Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients? Am J Med 123(9):785–789. [Epub 2010 Jul 23]

    Google Scholar 

  69. Gallandat Huet RC, Siemons AW, Baus D, et al (2000) A novel hydroxyethyl starch (Voluven) for effective perioperative plasma volume substitution in cardiac surgery. Can J Anaesth 47:1207–1215

    Google Scholar 

  70. Karanko MS, Klossner JA, Laaksonen VO (1987) Restoration of volume by crystalloid versus colloid after coronary artery bypass: hemo- dynamics, lung water, oxygenation, and outcome. Crit Care Med 15:559–566

    Article  PubMed  CAS  Google Scholar 

  71. Verheij J, van Lingen A, Beishuizen A et al (2006) Cardiac response is greater for colloid than saline fluid loading after cardiac or vascular surgery. Intensive Care Med 32:1030–1038

    Article  PubMed  CAS  Google Scholar 

  72. Boldt J, Haisch G, Suttner S, Kumle B, Schellhaass A (2002) Effects of a new modified, balanced hydroxyethyl starch preparation (Hextend) on measures of coagulation. Br J Anaesth 89:72

    Article  Google Scholar 

  73. Nielsen VG (2006) Effects of Hextend hemodilution on plasma coagulation kinetics in the rabbit: role of factor XIII-mediated fibrin polymer crosslinking. J Surg Res 132:17–22

    Article  PubMed  CAS  Google Scholar 

  74. Niemi TT, Kuitunen AH (2005) Artificial colloids impair haemostasis. An in vitro study using thromboelastometry coagulation analysis. Acta Anaesthesiol Scand 49:373–378

    Article  PubMed  CAS  Google Scholar 

  75. Boldt J, Knothe C, Zickmann B, Andres P, Dapper F, Hempelmann G (1993) Influence of different volume therapies on platelet function in patients undergoing cardiopulmonary bypass. Anesth Analg 76:1185–1190

    PubMed  CAS  Google Scholar 

  76. Niemi TT, Kuitunen AH (1998) Hydroxyethyl starch impairs in vitro coagulation. Acta Anaesthesiol Scand 42:1104–1109

    Article  PubMed  CAS  Google Scholar 

  77. Niemi TT, Suojaranta-Ylinen RT, Kukkonen SI, Kuitunen AH (2006) Gelatin and hydroxyethyl starch, but not albumin, impair hemostasis after cardiac surgery. Anesth Analg 102:998–1006

    Article  PubMed  CAS  Google Scholar 

  78. Niemi TT, Kuitunen AH (2005) Artificial colloids impair haemostasis. An in vitro study using thromboelastometry coagulation analysis. Acta Anaesthesiol Scand 49:373–378

    Article  PubMed  CAS  Google Scholar 

  79. Boldt J, Wolf M, Mengistu A (2007) A new plasma adapted hydroxyethylstarch preparation: in vitro coagulation studies using thrombelastography and whole blood aggregometry. Anesth Analg 104:425–430

    Article  PubMed  CAS  Google Scholar 

  80. Schols SE, Lance MD, Feijge MA (2010) Impaired thrombin generation and fibrin clot formation in patients with dilutional coagulopathy during major surgery. Thromb Haemost 103:318–328

    Article  PubMed  CAS  Google Scholar 

  81. Van der Linden P, Ickx BE (2006) The effects of colloid solutions on hemostasis. Can J Anaesth 53:30–39

    Article  Google Scholar 

  82. Bergqvist D (1998) Modern aspects of prophylaxis and therapy for venous thromboembolic disease. Aust N Z J Surg 68:463–468

    Article  PubMed  CAS  Google Scholar 

  83. Clagett GP, Anderson FAJ, Geerts W et al (1998) Prevention of venous thromboembolism. Chest 114:531S–60S

    Article  PubMed  CAS  Google Scholar 

  84. Ljungstrom KG (1983) Dextran prophylaxis of fatal pulmonary embolism. World J Surg 7:767–772

    Article  PubMed  CAS  Google Scholar 

  85. Aberg M, Hedner U, Bergentz SE (1979) Effect of dextran on factor VIII (antihemophilic factor) and platelet function. Ann Surg 189:243–247

    Article  PubMed  CAS  Google Scholar 

  86. Batlle J, del Rio F, Lopez FM et al (1985) Effect of dextran on factor VIII/von Willebrand factor structure and function. Thromb Haemost 54:697–699

    PubMed  CAS  Google Scholar 

  87. Mardel SN, Saunders FM, Allen H et al (1998) Reduced quality of clot formation with gelatin-based plasma substitutes. Br J Anaesth 80:204–207

    PubMed  CAS  Google Scholar 

  88. Aberg M, Hedner U, Bergentz SE (1979) The antithrombotic effect of dextran. Scand J Haematol Suppl 34:61–68

    PubMed  CAS  Google Scholar 

  89. de Jonge E, Levi M, Berends F et al (1998) Impaired haemostasis by intravenous administration of a gelatin-based plasma expander in human subjects. Thromb Haemost 79:286–290

    PubMed  Google Scholar 

  90. Beyer R, Harmening U, Rittmeyer O et al (1997) Use of modified fluid gelatin and hydroxyethyl starch for colloidal volume replacement in major orthopaedic surgery. Br J Anaesth 78:44–50

    PubMed  CAS  Google Scholar 

  91. Boldt J, Knothe C, Zickmann B et al (1993) Influence of different intravascular volume therapies on platelet function in patients undergoing cardiopulmonary bypass. Anesth Analg 76:1185–1190

    PubMed  CAS  Google Scholar 

  92. Mortelmans YJ, Vermaut G, Verbruggen AM et al (1995) Effects of 6% hydroxyethyl starch and 3% modified fluid gelatin on intravascular volume and coagulation during intraoperative hemodilution. Anesth Analg 81:1235–1242

    PubMed  CAS  Google Scholar 

  93. Trumble ER, Muizelaar JP, Myseros JS et al (1995) Coagulopathy with the use of hetastarch in the treatment of vasospasm. J Neurosurg 82:44–47

    Article  PubMed  CAS  Google Scholar 

  94. Cope JT, Banks D, Mauney MC et al (1997) Intraoperative hetastarch infusion impairs hemostasis after cardiac operations. Ann Thorac Surg 63:78–82

    Article  PubMed  CAS  Google Scholar 

  95. Villarino ME, Gordon SM, Valdon C et al (1992) A cluster of severe postoperative bleeding following open heart surgery. Infect Control Hosp Epidemiol 13:282–287

    Article  PubMed  CAS  Google Scholar 

  96. Salmon JB, Mythen MG (1993) Pharmacology and physiology of colloids. Blood Rev 7:114–120

    Google Scholar 

  97. Treib J, Haass A, Pindur G (1997) Coagulation disorders caused by hydroxyethyl starch. Thromb Haemost 78:974–983

    PubMed  CAS  Google Scholar 

  98. Jorgensen KA, Stoffersen E (1980) On the inhibitory effect of albumin on platelet aggregaion. Thromb Res 17:13–18

    Article  PubMed  CAS  Google Scholar 

  99. Kim SB, Chi HS, Park JS et al (1999) Effect of increasing serum albumin on plasma Ddimer, von Willebrand factor, and platelet aggregation in CAPD patients. Am J Kidney Dis 33:312–317

    Article  PubMed  CAS  Google Scholar 

  100. Sanofi-Aventis (2007) DDAVP package insert. Bridgewater, NJ

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Anesthesia and Intensive Care, Cattinara Hospital, University of Trieste, Trieste, Italy

    Emanuele Marras, Luigi Lo Nigro & Giorgio Berlot

Authors
  1. Emanuele Marras
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Luigi Lo Nigro
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Giorgio Berlot
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Emanuele Marras .

Editor information

Editors and Affiliations

  1. , Department of Anesthesia and Intensive C, University of Trieste, Strada di Fiume 447, Trieste, I-34149, Italy

    Giorgio Berlot

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer-Verlag Italia

About this chapter

Cite this chapter

Marras, E., Lo Nigro, L., Berlot, G. (2012). Anticoagulation Therapy in ICU Patients. In: Berlot, G. (eds) Hemocoagulative Problems in the Critically Ill Patient. Springer, Milano. https://doi.org/10.1007/978-88-470-2448-9_3

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-2448-9_3

  • Published:

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-2447-2

  • Online ISBN: 978-88-470-2448-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation